Consists of Clobetasol Topical, Miconazole Topical, Neomycin Topical
|
||
Neoclobenate-GM Dosage |
||
Consists of Clobetasol Topical, Miconazole Topical, Neomycin Topical
Generic name: CLOBETASOL PROPIONATE 0.05g in 1mL
Dosage form: topical spray
See also:
The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.
Clobetasol Topical (Neoclobenate-GM)® Spray, 0.05% is for topical use only, and not for ophthalmic, oral or intravaginal use.
Clobetasol Topical (Neoclobenate-GM)® Spray, 0.05% should be sprayed directly onto the affected skin areas twice daily and rubbed in gently and completely.
The total dosage should not exceed 50 g (59 mL or 2 fluid ounces) per week because of the potential for the drug to suppress the hypothalamic-pituitary-adrenal (HPA) axis. Do not use more than 26 sprays per application or 52 sprays per day.
Clobetasol Topical (Neoclobenate-GM)® Spray, 0.05% contains a topical corticosteroid; therefore treatment should be limited to 4 weeks. Therapy should be discontinued when control has been achieved. Treatment beyond 2 weeks should be limited to localized lesions of moderate to severe plaque psoriasis that have not sufficiently improved after the initial 2 weeks of treatment with Clobetasol Topical (Neoclobenate-GM)® Spray, 0.05%. If no improvement is seen within 2 weeks, reassessment of diagnosis may be necessary. Before prescribing for more than 2 weeks, any additional benefits of extending treatment to 4 weeks should be weighed against the risk of HPA axis suppression.
Use in pediatric patients younger than 18 years is not recommended because of the potential for HPA axis suppression see [Use in Specific Populations (8.4)].
Unless directed by physician, Clobetasol Topical (Neoclobenate-GM)® Spray, 0.05% should not be used with occlusive dressings.
Medicine used on the skin is not likely to be affected by other drugs you use. But many drugs can interact with each other. Tell each of your health care providers about all medicines you use, including prescription and over-the-counter medicines, vitamins, and herbal products.
Clobetasol Topical (Neoclobenate-GM) drug interactions (in more detail)
Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin. Avoid combination
Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy. Monitor therapy
Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. Monitor therapy
Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase. Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase. Larger doses of hyaluronidase may be required. Consider therapy modification
Ritodrine: Corticosteroids may enhance the adverse/toxic effect of Ritodrine. Monitor therapy
Generic name: Miconazole Nitrate 200mg; Miconazole Nitrate 10mg in 0.5g
Dosage form: vaginal cream, vaginal suppositories
See also:
The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.
It is not likely that other drugs you take orally or inject will have an effect on topically applied miconazole. But many drugs can interact with each other. Tell each of your health care providers about all medicines you use, including prescription and over-the-counter medicines, vitamins, and herbal products.
The effects of some drugs can change if you take other drugs or herbal products at the same time. This can increase your risk for serious side effects or may cause your medications not to work correctly. These drug interactions are possible, but do not always occur. Your doctor or pharmacist can often prevent or manage interactions by changing how you use your medications or by close monitoring.
To help your doctor and pharmacist give you the best care, be sure to tell your doctor and pharmacist about all the products you use (including prescription drugs, nonprescription drugs, and herbal products) before starting treatment with this product. While using this product, do not start, stop, or change the dosage of any other medicines you are using without your doctor's approval.
Some products that may interact with this drug include: warfarin.
Some products that may increase the risk of vaginal yeast infections include antibiotics, corticosteroids (such as prednisone), and drugs that suppress the immune system (such as cyclosporine, methotrexate).
This document does not contain all possible drug interactions. Keep a list of all the products you use. Share this list with your doctor and pharmacist to lessen your risk for serious medication problems.
Applies to the following strength(s): 125 mg/5 mL; 500 mg
The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.
1 g orally every hour for 4 doses followed by 1 g every 4 hours for 5 doses
Alternate dosing: 6 g/day orally divided every 4 hours for 2 to 3 days
4 to 12 g/day orally divided every 4 to 6 hours for 5 to 6 days
4 to 12 g/day orally divided every 4 to 6 hours for 5 to 6 days
3 g/day orally in 4 divided doses
The safety and efficacy of Neomycin Topical (Neoclobenate-GM) in children less than 18 years of age has not been established. However, the use of Neomycin Topical (Neoclobenate-GM) may be appropriate is some situations.
Less than 1 month: 50 mg/kg/day orally divided every 6 hours
1 year to 18 years: 50 to 100 mg/kg/day orally divided every 6 hours
The safety and efficacy of Neomycin Topical (Neoclobenate-GM) in children less than 18 years of age has not been established. However, the use of Neomycin Topical (Neoclobenate-GM) may be appropriate is some situations.
1 month to 18 years: 50 to 100 mg/kg/day orally divided every 6 to 8 hours for 5 to 6 days
The safety and efficacy of Neomycin Topical (Neoclobenate-GM) in children less than 18 years of age has not been established. However, the use of Neomycin Topical (Neoclobenate-GM) may be appropriate is some situations.
1 month to 18 years: 50 to 100 mg/kg/day orally divided every 6 to 8 hours for 5 to 6 days
The safety and efficacy of Neomycin Topical (Neoclobenate-GM) in children less than 18 years of age has not been established. However, the use of Neomycin Topical (Neoclobenate-GM) may be appropriate is some situations.
Less than 1 month: 50 mg/kg/day orally divided every 6 hours
1 year to 18 years: 50 mg/kg/day orally divided every 6 hours for 2 to 3 days
Patients with impaired renal function have a high risk of developing nephrotoxicity and ototoxicity with oral Neomycin Topical (Neoclobenate-GM). Use of a less nephrotoxic medication may be a consideration for this patient.
In chronic hepatic insufficiency, it may be necessary to give Neomycin Topical (Neoclobenate-GM) sulfate 4 g daily for an indefinite period, if less toxic drugs cannot be used.
Caution should be used when administering Neomycin Topical (Neoclobenate-GM) to patients with renal impairment. Dose reduction should be considered in these patients.
To minimize the risk of toxicity use the lowest possible dose and the shortest possible treatment period to control the condition. Treatment periods of longer than 2 weeks are not recommended.
Do not use in patients with intestinal obstruction.
Do not use in patients with inflammatory or ulcerative gastrointestinal disease due to the potential for increased gastrointestinal absorption of the drug.
Patients should be monitored for nephrotoxicity and ototoxicity.
Neomycin Topical (Neoclobenate-GM) should be used with caution in patients with hearing impairment, renal impairment or neuromuscular disorders.
Patients with impaired renal function have a high risk of developing nephrotoxicity and ototoxicity with oral Neomycin Topical (Neoclobenate-GM). Use of a less nephrotoxic medication may be a consideration for this patient.
Neomycin Topical (Neoclobenate-GM) can harm your kidneys, and this effect is increased when you also use certain other medicines harmful to the kidneys. Before using Neomycin Topical (Neoclobenate-GM), tell your doctor about all other medicines you use. Many other drugs (including some over-the-counter medicines) can be harmful to the kidneys.
Before you take Neomycin Topical (Neoclobenate-GM), tell your doctor if you are using any other antibiotics, such as
amikacin (Amikin)
amphotericin-B (Amphotec);
bacitracin (Baci IM);
colistimethate (Coly Mycin M);
gentamicin (Garamycin);
kanamycin (Kantrex);
paromomycin (Humatin, Paromycin);
polymyxin B sulfate;
penicillin V (PC Pen VK);
streptomycin;
tobramycin (Nebcin, Tobi); or
vancomycin (Vancocin, Vancoled).
Tell your doctor about all other medicines you use, especially:
cisplatin (Platinol);
digoxin (digitalis, Lanoxin, Lanoxicaps);
methotrexate (Rheumatrex, Trexall);
vitamin B-12;
antiviral medicines such as adefovir (Hepsera), cidofovir (Vistide), or tenofovir (Viread);
a blood thinner such as warfarin (Coumadin, Jantoven);
a botulism toxin medication (Botox, Dysport, Myobloc, Xeomin, and others); or
a diuretic (water pill) such as bumetanide (Bumex), ethacrynic acid (Edecrin), furosemide (Lasix), or torsemide (Demadex).
This list is not complete and other drugs may interact with Neomycin Topical (Neoclobenate-GM). Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.
Caution should be taken in concurrent or serial use of other neurotoxic and/ or nephrotoxic drugs because of possible enhancement of the nephrotoxicity and/or ototoxicity of Neomycin Topical (Neoclobenate-GM).
Caution should also be taken in concurrent or serial use of other aminoglycosides and polymyxins because they may enhance Neomycin Topical (Neoclobenate-GM)ís nephrotoxicity and/or ototoxicity and potentiate Neomycin Topical (Neoclobenate-GM) sulfateís neuromuscular blocking effects.
Oral Neomycin Topical (Neoclobenate-GM) inhibits the gastrointestinal absorption of penicillin V, oral vitamin B-12, methotrexate and 5-fluorouracil. The gastrointestinal absorption of digoxin also appears to be inhibited. Therefore, digoxin serum levels should be monitored.
Oral Neomycin Topical (Neoclobenate-GM) sulfate may enhance the effect of coumarin in anticoagulants by decreasing vitamin K availability.
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
|